Our ability to leverage Tempus’ expertise in bioinformatics and technology infrastructure will be a major asset in our arsenal of targeted therapies and novel clinical trials."
Leonidas Platanias, MD, PhD
Director of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University
The goals of both research projects are to improve patient quality of life by limiting exposure to ineffective agents and decreasing unnecessary toxicity and, most importantly, to improve survival by allowing for more individualized cancer therapy. The collaboration with Tempus allows us to generate high-quality, clinical-grade tumor sequencing results that will benefit the research objectives and potentially impact ongoing patient care. This is a valuable opportunity for laboratory investigators, clinicians, and patients alike."
Minetta Liu, M.D.
Research Chair for the Division of Medical Oncology and Principal Investigator of the immunotherapy-focused research study
As the cost to gather molecular data has come down over time, it's more important than ever that our physicians are armed with the most relevant and state-of-the art tools that they need to do their job. At Rush, we are committed to innovation and, through our partnership with Tempus, we expect to be able to usher in an unprecedented era of advancement as it relates to doing what is and has always been first and foremost at Rush - caring for our patients."
Dr. Ranga Krishnan
Dean of Rush Medical College, and Senior Vice President at Rush
As we continue to strive to deliver the best care possible to our patients, it is important to learn as much as we can about their disease and treatments that may be best suited to them. Working with Tempus allows our researchers and clinicians to gather deeper insight into their patient’s cancer that should ultimately lead to more effective treatment.”
David Pearce, PhD
Executive Vice President, Innovation & Research, Sanford Health
At The University of Pennsylvania’s Abramson Cancer Center, we believe that the cure for cancer is not only within reach, it's also within each of us. We are excited to partner with Tempus, who bring their sequencing and analytic capabilities to our renowned team of researchers."
Robert H. Vonderheide, MD, DPhil
Hanna Wise Professor in Cancer Research at the Perelman School of Medicine at the University of Pennsylvania and Associate Director for Translational Research at the Abramson Cancer Center